Joseph Birkett, Executive Director at Aura Biosciences – Obinutuzumab's Approval, CDK9 Trial Regret, CRO Reliance, and Building Respectful Cultures
Joseph (Joe) Birkett, Executive Director of Medical Affairs at Aura Biosciences, joined our podcast to share what he’s learned over two decades in oncology drug development, including the career-defining moments and the painful missteps that shaped his approach.
Joe speaks openly about his proudest contribution—helping lead Obinutuzumab to regulatory approval—and contrasts it with one of his lowest points: watching leadership ignore safety concerns around a CDK9 inhibitor that ultimately failed in the clinic.
Here's what you're in:
- How Joe helped lead Obinutuzumab to Phase III and approval.
- The fallout of pushing a CDK9 inhibitor with flawed preclinical data.
- His experience as a CEO and the lessons he carries forward.
Timestamps:
02:22 Working on Obinutuzumab and its approval
04:51 Dealing with toxic leadership and moving on
07:18 Introducing Aura Biosciences
15:01 What Joe looks for when hiring at Aura
19:32 Why companies rely too much on CROs
24:44 The problem with safe bets and risk-averse R&D
29:47 Quickfire round
About Joe
Joseph Birkett is the Executive Director of Medical Affairs at Aura Biosciences, a clinical-stage biotech company developing virus-like drug conjugates (VDCs) to treat cancers such as uveal melanoma. Joe has 25 years of oncology drug development experience, contributing to the approval of seven oncology drugs across multiple disease areas.
Prior to joining Aura Biosciences, he served as CEO of a stealth-mode EU biotech and is the founder of Crest Pharma. He holds a PhD in Psychiatric Medicine from King’s College London, and his passion extends beyond drug development to longevity, health, and wellness.
Connect with Joe
LinkedIn: https://www.linkedin.com/in/joseph-birkett-14572410/
Company Website: https://www.aurabiosciences.com/
About me
My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.
In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.
Connect with me:
LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/
Website: https://www.discera-search.com/
Opinions and comments expressed by the guest do not represent the company and are fully their own.
